A Novel Oncolytic Modified Measles Virus Is A Promising Candidate For Cancer Therapy | 57379
Journal of Cancer Science & Therapy
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Oncolytic virus therapy is a promising therapy for various tumor types. We previously reported that a wild-type measles
virus (MV) efficiently infects and shows high oncolytic activity to breast cancer cells. Since wild type MV infects immune
cells using signaling lymphocyte activation molecule (SLAM) as a receptor, and causes its pathogenicity in host animals, we
generated a recombinant MV selectively unable to use SLAM (rMV-SLAMblind). The rMV-SLAM blind lost infectivity to
lymphoid cells, but maintained its infectivity to breast cancer cells using another receptor of MV, PVRL4 (poliovirus receptor
related-4)/Nectin-4. Nectin-4 is hardly expressed in other tissues except placenta in healthy adults. Recent studies reported that
Nectin-4 expression is up-regulated in various types of tumor cells, including breast cancer and non-small-cell lung cancer,
which is the leading cause of cancer-related death. We examined the efficacy of rMV-SLAMblind on various cell lines derived
from refractory cancers, in which Nectin-4/PVRL4 was expressed. The virus showed high oncolytic activity against them and
also effectively suppressed tumor mass growth in xenotransplanted immunodeficient mice. Thus, rMV-SLAMblind should be
a promising candidate of a novel therapeutic agent for caner treatment.
Chieko Kai is a full Professor and Director of Animal Research Center, Institute of Medical Science, the University of Tokyo since 1999, and is also a Professor of International Research Center for Infectious Diseases, in the same institute. She is a member of Science Council of Japan. Her major interests are mechanisms of pathogenisity of RNA viruses, and to control viral diseases. Her current research focus is on developing a novel cancer therapy using oncolytic viruses by genetic engineering.